These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

177 related articles for article (PubMed ID: 36476293)

  • 1. Cognition in patients treated with targeted therapy for chronic myeloid leukemia: a controlled comparison.
    Hyland KA; Eisel SL; Hoogland AI; Root JC; Bowles K; James B; Nelson AM; Booth-Jones M; Jacobsen PB; Ahles TA; Jim HSL; Gonzalez BD
    Leuk Lymphoma; 2023 Feb; 64(2):415-423. PubMed ID: 36476293
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Quality of life outcomes in patients with chronic myeloid leukemia treated with tyrosine kinase inhibitors: a controlled comparison.
    Phillips KM; Pinilla-Ibarz J; Sotomayor E; Lee MR; Jim HS; Small BJ; Sokol L; Lancet J; Tinsley S; Sweet K; Komrokji R; Jacobsen PB
    Support Care Cancer; 2013 Apr; 21(4):1097-103. PubMed ID: 23179489
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Correlates of fatigue severity in patients with chronic myeloid leukemia treated with targeted therapy.
    Oswald LB; Hyland KA; Eisel SL; Hoogland AI; Knoop H; Nelson AM; Pinilla-Ibarz J; Sweet K; Jacobsen PB; Jim HSL
    Support Care Cancer; 2022 Jan; 30(1):87-94. PubMed ID: 34231041
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Lower tumor burden is associated with better cognitive function in patients with chronic phase chronic myeloid leukemia.
    Li Z; Peng L; Li Y; Zhang J; Jiang Q
    Leuk Lymphoma; 2022 Oct; 63(10):2352-2363. PubMed ID: 35543618
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cognitive Behavioral Therapy for Treatment-Related Fatigue in Chronic Myeloid Leukemia Patients on Tyrosine Kinase Inhibitors: A Mixed-Method Study.
    Poort H; Onghena P; Abrahams HJG; Jim HSL; Jacobsen PB; Blijlevens NMA; Knoop H
    J Clin Psychol Med Settings; 2019 Dec; 26(4):440-448. PubMed ID: 30747340
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Fatigue Perpetuating Factors as Mediators of Change in a Cognitive Behavioral Intervention for Targeted Therapy-Related Fatigue in Chronic Myeloid Leukemia: A Pilot Study.
    Hyland KA; Nelson AM; Eisel SL; Hoogland AI; Ibarz-Pinilla J; Sweet K; Jacobsen PB; Knoop H; Jim HSL
    Ann Behav Med; 2022 Feb; 56(2):137-145. PubMed ID: 33991085
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Internet-assisted cognitive behavioral intervention for targeted therapy-related fatigue in chronic myeloid leukemia: Results from a pilot randomized trial.
    Jim HSL; Hyland KA; Nelson AM; Pinilla-Ibarz J; Sweet K; Gielissen M; Bulls H; Hoogland AI; Jacobsen PB; Knoop H
    Cancer; 2020 Jan; 126(1):174-180. PubMed ID: 31553815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Patient reported outcome of tyrosine kinase inhibitor related side effects and their impact on daily life in Chinese patients with chronic myeloid leukemia in the chronic phase].
    Yu L; Wang HB; Jiang Q
    Zhonghua Xue Ye Xue Za Zhi; 2016 Nov; 37(11):929-935. PubMed ID: 27995875
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Assessment of Outcomes After Stopping Tyrosine Kinase Inhibitors Among Patients With Chronic Myeloid Leukemia: A Nonrandomized Clinical Trial.
    Atallah E; Schiffer CA; Radich JP; Weinfurt KP; Zhang MJ; Pinilla-Ibarz J; Kota V; Larson RA; Moore JO; Mauro MJ; Deininger MWN; Thompson JE; Oehler VG; Wadleigh M; Shah NP; Ritchie EK; Silver RT; Cortes J; Lin L; Visotcky A; Baim A; Harrell J; Helton B; Horowitz M; Flynn KE
    JAMA Oncol; 2021 Jan; 7(1):42-50. PubMed ID: 33180106
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Anxiety and depression associated with tyrosine kinase inhibitor discontinuation in patients with chronic myeloid leukemia.
    Sogawa R; Kimura S; Yakabe R; Mizokami Y; Tasaki M; Sueoka-Aragane N; Narisawa Y; Kimura S
    Int J Clin Oncol; 2018 Oct; 23(5):974-979. PubMed ID: 29651584
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Variables associated with self-reported anxiety and depression symptoms in patients with chronic myeloid leukemia receiving tyrosine kinase inhibitor therapy.
    Shi D; Li Z; Li Y; Jiang Q
    Leuk Lymphoma; 2021 Mar; 62(3):640-648. PubMed ID: 33150806
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
    Phuar HL; Begley CE; Chan W; Krause TM
    J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Health-related quality of life in patients with chronic myeloid leukemia receiving first-line therapy with nilotinib.
    Efficace F; Castagnetti F; Martino B; Breccia M; D'Adda M; Angelucci E; Stagno F; Cottone F; Malato A; Trabacchi E; Capalbo SF; Gobbi M; Visani G; Salvucci M; Capodanno I; Tosi P; Tiribelli M; Scortechini AR; Levato L; Maino E; Binotto G; Gugliotta G; Vignetti M; Baccarani M; Rosti G
    Cancer; 2018 May; 124(10):2228-2237. PubMed ID: 29499087
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differentiation status of primary chronic myeloid leukemia cells affects sensitivity to BCR-ABL1 inhibitors.
    Pietarinen PO; Eide CA; Ayuda-Durán P; Potdar S; Kuusanmäki H; Andersson EI; Mpindi JP; Pemovska T; Kontro M; Heckman CA; Kallioniemi O; Wennerberg K; Hjorth-Hansen H; Druker BJ; Enserink JM; Tyner JW; Mustjoki S; Porkka K
    Oncotarget; 2017 Apr; 8(14):22606-22615. PubMed ID: 28186983
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Relationship between Carnitine Deficiency and Tyrosine Kinase Inhibitor Use in Patients with Chronic Myeloid Leukemia.
    Iriyama N; Miura K; Uchino Y; Takahashi H; Nakagawa M; Iizuka K; Hamada T; Koike T; Kurihara K; Nakayama T; Takei M; Hatta Y; Nakamura H
    Chemotherapy; 2022; 67(2):96-101. PubMed ID: 34839292
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Comparison of Hepatotoxicity Associated With New BCR-ABL Tyrosine Kinase Inhibitors vs Imatinib Among Patients With Chronic Myeloid Leukemia: A Systematic Review and Meta-analysis.
    Wang Z; Wang X; Wang Z; Feng Y; Jia Y; Jiang L; Xia Y; Cao J; Liu Y
    JAMA Netw Open; 2021 Jul; 4(7):e2120165. PubMed ID: 34292334
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Anxiety exacerbation in a patient with chronic myeloid leukemia receiving dasatinib and venlafaxine.
    Bell C; Signorelli J; Hobbs G
    J Oncol Pharm Pract; 2023 Oct; 29(7):1762-1765. PubMed ID: 37282628
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Planned Pregnancy in Female Patients with Chronic Myeloid Leukemia Receiving Tyrosine Kinase Inhibitor Therapy.
    Dou X; Qin Y; Huang X; Jiang Q
    Oncologist; 2019 Nov; 24(11):e1141-e1147. PubMed ID: 31186377
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The costs of treating and not treating patients with chronic myeloid leukemia with tyrosine kinase inhibitors among Medicare patients in the United States.
    Seymour EK; Ruterbusch JJ; Winn AN; George JA; Beebe-Dimmer JL; Schiffer CA
    Cancer; 2021 Jan; 127(1):93-102. PubMed ID: 33119175
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Health-Related Quality of Life of Patients with Chronic Myeloid Leukemia as Measured by Patient-Reported Outcomes: Current State and Future Directions.
    Schoenbeck KL; Flynn KE
    Curr Hematol Malig Rep; 2021 Dec; 16(6):491-499. PubMed ID: 34648119
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.